Analysis of CBP (CREBBP) gene deletions in Rubinstein‐Taybi syndrome patients using real‐time quantitative PCR

Rubinstein‐Taybi syndrome (RTS) is a well‐defined syndrome characterized by facial abnormalities, broad thumbs, broad big toes, and growth and mental retardation as the main clinical features. RTS was shown to be associated with disruption of the CREB–binding protein gene CBP (CREBBP), either by gross chromosomal rearrangements or by point mutations. Translocations and inversions involving chromosome band 16p13.3 form the minority of CBP mutations, whereas microdeletions occur more frequently (about 10%). Most deletion studies in RTS are performed by FISH analysis, and five cosmids must be used to cover the whole of the CBP gene, which spreads over 150 kb. Here we report the design of gene dosage assays by real‐time quantitative PCR that are targeted on three exons located respectively at the 5′ end (exon 2), in the middle (exon 12), and at the 3′ end (exon 30) of the CBP gene. This technique proved to be efficient and powerful in finding deletions and complementary to the other available techniques, since it allowed us to identify deletions at the 3′ end of the gene that had been missed by FISH analysis, and to refine some deletion breakpoints. Our results therefore suggest that real‐time quantitative PCR is a useful technique to be included in the deletion search in RTS patients. Hum Mutat 23:278–284, 2004. © 2004 Wiley‐Liss, Inc.

[1]  C. Cruaud,et al.  Molecular analysis of the CBP gene in 60 patients with Rubinstein-Taybi syndrome , 2002, Journal of medical genetics.

[2]  J. Morton,et al.  Fragile X syndrome is less common than previously estimated. , 1997, Journal of medical genetics.

[3]  Á. Carracedo,et al.  Rapid real-time fluorescent PCR gene dosage test for the diagnosis of DNA duplications and deletions. , 2000, Clinical chemistry.

[4]  A. Lang,et al.  The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. , 2001, Human molecular genetics.

[5]  N. Tommerup,et al.  Tentative assignment of a locus for Rubinstein-Taybi syndrome to 16p13.3 by a de novo reciprocal translocation, t(7;16)(q34;p13.3). , 1992, American journal of medical genetics.

[6]  L. Gaunt,et al.  Rubinstein-Taybi syndrome with deletions of FISH probe RT1 at 16p13.3: two UK patients. , 1996, Journal of medical genetics.

[7]  Y. Makita,et al.  Submicroscopic deletion of chromosome region 16p13.3 in a Japanese patient with Rubinstein-Taybi syndrome. , 1994, American journal of medical genetics.

[8]  R. Hennekam,et al.  Rubinstein-Taybi syndrome caused by a De Novo reciprocal translocation t(2;16)(q36.3;p13.3). , 2000, American journal of medical genetics.

[9]  Y. Kuroki,et al.  Rubinstein-Taybi syndrome with de novo reciprocal translocation t(2;16)(p13.3;p13.3). , 1991, American journal of medical genetics.

[10]  E. Mariman,et al.  Deletion at chromosome 16p13.3 as a cause of Rubinstein-Taybi syndrome: clinical aspects. , 1993, American journal of human genetics.

[11]  D. Lacombe,et al.  Confirmation of assignment of a locus for Rubinstein-Taybi syndrome gene to 16p13.3. , 1992, American journal of medical genetics.

[12]  G. Nicholson,et al.  Determination of gene dosage at the PMP22 and androgen receptor loci by quantitative PCR. , 1998, Clinical chemistry.

[13]  Masatoshi Hagiwara,et al.  Phosphorylated CREB binds specifically to the nuclear protein CBP , 1993, Nature.

[14]  M. Breuning,et al.  Conjunction dysfunction: CBP/p300 in human disease. , 1998, Trends in genetics : TIG.

[15]  D. Lacombe,et al.  Submicroscopic deletion of chromosome 16p13.3 in patients with Rubinstein-Taybi syndrome. , 1998, American journal of medical genetics.

[16]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[17]  S. Ring,et al.  Comparative multiplex dosage analysis detects whole exon deletions at the phenylalanine hydroxylase locus , 2003, Human mutation.

[18]  L. Deaven,et al.  Construction of a 1.2-Mb contig surrounding, and molecular analysis of, the human CREB-binding protein (CBP/CREBBP) gene on chromosome 16p13.3. , 1997, Genomics.

[19]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[20]  R. Hennekam,et al.  Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations , 2000, Journal of medical genetics.

[21]  E. Ringelstein,et al.  PCR-based strategy for the diagnosis of hereditary neuropathy with liability to pressure palsies and Charcot-Marie-Tooth disease type 1A , 1998, Neurology.

[22]  L. Jackson,et al.  Submicroscopic deletions at 16p13.3 in Rubinstein-Taybi syndrome: frequency and clinical manifestations in a North American population. , 1997, Journal of medical genetics.

[23]  Dominique Stoppa-Lyonnet,et al.  Rapid detection of novel BRCA1 rearrangements in high‐risk breast‐ovarian cancer families using multiplex PCR of short fluorescent fragments , 2002, Human mutation.

[24]  Johan T den Dunnen,et al.  Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. , 2002, American journal of human genetics.

[25]  H. Saal,et al.  Variation in microdeletions of the cyclic AMP-responsive element-binding protein gene at chromosome band 16p13.3 in the Rubinstein-Taybi syndrome. , 2000, American journal of medical genetics.